Resistance to anti-angiogenic therapy in patients with neovascular age-related macular degeneration | ||||
| Minia Journal of Medical Research | ||||
| Volume 30, Issue 1, March 2019, Page 212-216 PDF (106.52 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.223012 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mohamed A. Hamid; Sahar TA. Abdelaziz; Ahmed M. Sabry; Khaled M. Mourad; Azza A. Shehab | ||||
| Department of Ophthalmology, Minia University Hospital, Minia, Egypt | ||||
| Abstract | ||||
| Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in developed countries among individuals aged 50 years and older. The neovascular form of late AMD affects only 10% of patients but is responsible for most cases of severe vision loss due to the disease. Despite their good results in treatment of neovascular AMD, anti-angiogenic agents can be ineffective in a subset of patients considered resistant to therapy. Several mechanisms have been proposed to explain his phenomenon and, subsequently, different management strategies are currently under investigation to improve patient outcomes with anti-angiogenic therapy. | ||||
| Keywords | ||||
| anti-angiogenic; neovascular; macular degeneration | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 56 PDF Download: 114 |
||||
